Design Therapeutics (NASDAQ: DSGN)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.270 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Design Therapeutics (NASDAQ: DSGN) through any online brokerage.
There are no as such competitors for Design Therapeutics.
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by Wedbush on Tuesday, August 9, 2022. The analyst firm set a price target for 26.00 expecting DSGN to rise to within 12 months (a possible 1.68% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Design Therapeutics (NASDAQ: DSGN) is $25.57 last updated August 15, 2022, 8:00 PM UTC.
There are no upcoming dividends for Design Therapeutics.
Design Therapeutics’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for Design Therapeutics.
Design Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.